(Q48151074)

9 February 2018

title

Dual mTORC1 and mTORC2 inhibitor Palomid 529 penetrates the blood-brain barrier without restriction by ABCB1 and ABCG2. (English)

1 reference

9 February 2018

1 reference

4

Jos H Beijnen

1 reference

9 February 2018

author name string

Fan Lin

1

1 reference

9 February 2018

Levi Buil

2

1 reference

9 February 2018

David Sherris

3

1 reference

9 February 2018

Olaf van Tellingen

5

1 reference

9 February 2018

language of work or name

English

0 references

publication date

1 April 2013

1 reference

9 February 2018

International Journal of Cancer

published in

1 reference

9 February 2018

volume

133

1 reference

9 February 2018

issue

5

1 reference

9 February 2018

page(s)

1222-1233

1 reference

9 February 2018

Dysregulation of the TSC-mTOR pathway in human disease

cites work

1 reference

Ras, PI(3)K and mTOR signalling controls tumour cell growth

21 January 2018

1 reference

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

Mutations of the PIK3CA gene are rare in human glioblastoma.

21 January 2018

1 reference

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

21 January 2018

1 reference

Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance

21 January 2018

1 reference

Palomid 529, a novel small-molecule drug, is a TORC1/TORC2 inhibitor that reduces tumor growth, tumor angiogenesis, and vascular permeability

21 January 2018

1 reference

The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer

21 January 2018

1 reference

The TORC1/TORC2 inhibitor, Palomid 529, reduces tumor growth and sensitizes to docetaxel and cisplatin in aggressive and hormone-refractory prostate cancer cells.

21 January 2018

1 reference

Blood-brain barrier and chemotherapeutic treatment of brain tumors

21 January 2018

1 reference

Chemotherapy delivery issues in central nervous system malignancy: a reality check.

21 January 2018

1 reference

Distribution of gefitinib to the brain is limited by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2)-mediated active efflux

21 January 2018

1 reference

P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan

21 January 2018

1 reference

An unexpected synergist role of P-glycoprotein and breast cancer resistance protein on the central nervous system penetration of the tyrosine kinase inhibitor lapatinib (N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amin

21 January 2018

1 reference

Several major antiepileptic drugs are substrates for human P-glycoprotein

21 January 2018

1 reference

Role of P-glycoprotein and breast cancer resistance protein-1 in the brain penetration and brain pharmacodynamic activity of the novel phosphatidylinositol 3-kinase inhibitor GDC-0941.

21 January 2018

1 reference

Development of luciferase tagged brain tumour models in mice for chemotherapy intervention studies

21 January 2018

1 reference

PKSolver: An add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel

21 January 2018

1 reference

Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/- (triple-knockout) and wild-type mice

21 January 2018

1 reference

Kinetic analysis of the cooperation of P-glycoprotein (P-gp/Abcb1) and breast cancer resistance protein (Bcrp/Abcg2) in limiting the brain and testis penetration of erlotinib, flavopiridol, and mitoxantrone

21 January 2018

1 reference

Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.

21 January 2018

1 reference

Brain accumulation of sunitinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by oral elacridar and sunitinib coadministration.

21 January 2018

1 reference

Breast cancer resistance protein and P-glycoprotein limit sorafenib brain accumulation

21 January 2018

1 reference

Brain accumulation of dasatinib is restricted by P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) and can be enhanced by elacridar treatment

21 January 2018

1 reference

P-glycoprotein and breast cancer resistance protein influence brain distribution of dasatinib

21 January 2018

1 reference

The effect of breast cancer resistance protein and P-glycoprotein on the brain penetration of flavopiridol, imatinib mesylate (Gleevec), prazosin, and 2-methoxy-3-(4-(2-(5-methyl-2-phenyloxazol-4-yl)ethoxy)phenyl)propanoic acid (PF-407288) in mice

21 January 2018

1 reference

Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032)

21 January 2018

1 reference

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs

21 January 2018

1 reference

Targeting multidrug resistance in cancer

21 January 2018

1 reference

ATP-binding cassette, subfamily G (ABCG family).

21 January 2018

1 reference

Influence of blood-brain barrier efflux pumps on the distribution of vincristine in brain and brain tumors

21 January 2018

1 reference

Moderate Increase in Mdr1a/1b Expression Causes In vivo Resistance to Doxorubicin in a Mouse Model for Hereditary Breast Cancer

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/IJC.28126

1 reference

9 February 2018

1 reference

9 February 2018